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Summary 
We demonstrate here that CD59, an inhibitor of the membrane attack complex (MAC) of the 
complement system, is present in cell-free seminal plasma (SP) at a concentration of at least 20 
#g/ml. Analyses by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blotting, 
and Edman degradation indicated that this protein, SP CD59, was similar, if not identical, to 
CD59 isolated from erythrocyte (E) membranes (E CD59). Like purified E CD59, SP CD59 
also possesses a glycosyl phosphatidyl inositol (GPI) anchor and incorporates into the membranes 
of heterologous cells where it inhibits lysis by the human MAC. This phenomenon could be 
demonstrated not only if cells were incubated with purified SP CD59 but also if unfractionated 
SP were used. Further, CD59 in unfractionated SP bound to washed spermatozoa, increasing 
their membrane content of the protein. The mechanism by which this protein retains  its GPI 
anchor while apparently present in the fluid phase is of interest and was further investigated. 
Using the techniques of high-speed centrifugation, fast performance liquid chromatography 
fractionation, and electron microscopy,  we found that all detectable  SP CD59 was associated 
with vesicular extracellular  organelles. These organelles, named "prostasomes" were previously 
known to be present in SP and to interact with spermatozoa, although their function was uncertain. 
Interaction of heterologous E with prostasomes rendered the cells more resistant to lysis by human 
MACs. We propose that these organelles  represent a pool of CD59 from which protein lost 
from spermatozoa, perhaps as a result of low level complement attack or of normal membrane 
turnover, can be replenished. 
E 
xposure of spermatozoa to antisperm antibodies in the 
male (1,  2) and female  (3,  4) reproductive tracts and 
to functioning complement (C) in the female reproductive 
tract (4, 5) has been implicated in some cases of infertility. 
C-mediated immobilization of spermatozoa is dependent on 
membrane attack complex (MAC) 1 formation (6); control 
I Abbreviations used in this paper: CVF, cobra venom factor; GPE, guinea 
pig erythrocytes; GPI. glycosyl  phosphatidyl inositol; GVB, veronal-buffered 
saline  containing  1%  gelatin;  MAC,  membrane  attack  complex  (of 
complement);  NHS-C8D, normal  human serum depleted of C8; NHS- 
C9D,  normal  human serum  depleted  of C9; PlPLC,  phosphatidyl  in- 
ositol-speci~ phospholipase C; SP, seminal plasma; DAF, decay-accelerating 
factor; NIMIg, nonimmune mouse immunoglobulin; NIILlg, nonimmune 
rabbit  immunoglobulin;  TEM, transmission  electron microscopy. 
of MAC assembly on these cells may therefore be important 
for fertility. 
The MAC inhibitory protein CD59 is expressed on sper- 
matozoa, and antibody blocking of this protein increases sper- 
matozoal susceptibility to MAC-mediated killing in vitro (6). 
This, together with the recent identification of a form of CD59 
in amniotic fluid that retains the glycosyl phosphatidyl ino- 
sitol (GPI) anchor and functional activity even in the fluid 
phase (7), led us to investigate the possible presence and func- 
tion of CD59 in seminal plasma (SP). 
Herein the detection, purification, and characterization of 
SP CD59 is described. We show that, like erythrocyte CD59 
(E CD59) (8) and CD59 isolated  from amniotic fluid (7), 
SP CD59 has the capacity to insert into the membranes of 
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This phenomenon was GPI anchor dependent and occurred 
even when SP CD59 was present in unfractionated SP, sug- 
gesting that this protein may incorporate into cell membranes 
in vivo. We present data indicating that SP CD59 is carried 
on the membranes of vesicular, extracellular organelles.  Our 
results suggest that, as a result of interaction with these or- 
ganelles,  cell membranes (both of heterologous cells and of 
washed human spermatozoa) acquire bound CD59 molecules. 
Materials and Methods 
Reagents for SDS PAGE were obtained from Bio-pad Laborato- 
ries (Richmond, CA). Phosphatidyl inositol-specific  phospholipase 
C (PIPLC; from Bacillus thuringiensis) was from two sources: Penin- 
sula Laboratories, Europe (St. Helen's, UK) and ICN Biomedicals 
Inc. (Costa Mesa, CA). Unless otherwise started, all other chem- 
icals were from Sigma Chemical Co. (St. Louis, MO). 
Antibodies.  Mouse  mAb BRIC 229 (anti-CD59) was from Bin- 
products Laboratories  (Elstree, Hefts, UK). Mouse mAb A35 (anti- 
CD59),  rat mAb YTH 53.1 (anti-CD59), and rabbit polyclonal 
Rb476 (anti-CD59) IgG were the gifts of Dr. A. Davies (Depart- 
ment of  Medical  Biochemistry,  University  of  Wales College  of  Medi- 
cine). Mouse mAb GB24 (anti-membrane cofactor protein [MCP]) 
was a gift of Dr. B. L. Hsi (INSERM U210, Faculte de Medecine, 
Nice, France). Mouse mAb  IH6  (anti-decay-accelerating factor 
[DAF]) was a gift of Dr. T. Kinoshita (Department of Immuno- 
regulation, Research Institute for Microbiological  Diseases, Osaka 
University, Osaka, Japan). Nonimmune mouse IgG (NIMIg) and 
rabbit IgG (NIRIg) preparations were purchased from Sigma  Chem- 
ical Co. FITC-conjugated goat anti-mouse IgG (GAM-FITC) was 
from Sigma Chemical Co.; alkaline phosphatase-conjugated goat 
anti-mouse IgG (GAM-AP) and goat anti-rabbit IgG (GAR-AP) 
were from Bio-Rad Laboratories; and goat anti-mouse IgG con- 
jugated with 12-nm gold particles (GAM-gold) was from Jackson 
Immunoresearch Laboratories Inc. (West Grove, PA). 
Cells, Sera, and Complement Components.  Guinea  pig E (GPE) 
were from Crane Laboratories (Syracuse, NY). The 3T3 mouse 
fibroblast cell line was obtained from the American Type Cell Cul- 
ture Collection (Rockville, MD), and stably transfected 3T3 cells 
expressing human MCP (3T3-MCP ceils) were prepared in our 
laboratories. C9-depleted normal human  (NHS-C9D)  and C8- 
depleted normal human serum (NHS-C8D) were prepared by pas- 
sage of normal human serum over monoclonal immunoa~nity 
columns. C8 and C9 were prepared by immunoaf~nity chroma- 
tography (9, 10) or were purchased from Sigma  Chemical  Co. Cobra 
venom factor (CVF) was prepared by the method of Vogel and 
Muller-Eberhard (11). E CD59 and urine CD59, prepared as de- 
scribed (8), were gifts of Dr. A. Davies. Purified membrane DAF 
(mDAF) and a purified preparation of a recombinant, anchor- 
negative, secreted form of DAF (sDAF) were gifts of Dr. I. Caras 
(Genentech Inc., South San Francisco, CA). 
Collection and Storage of  SP.  Samples  of semen (1-3 ml) provided 
by healthy donors were allowed to liquefy at room temperature 
for 30 min. Cells and debris were then removed  by centrifugation 
at 10,000 g for 10 min. For functional experiments the cell-free 
SP thus prepared was used immediately. Samples  collected  for sub- 
sequent purification of SP CD59 were stored separately  at - 20~ 
Preparation  of  Live Stx,  rmatozoa.  Live  spermatozoa  were prepared 
by a modification of the "swim up" technique of Hellema and 
Rumke (12) as previously  described (6). After washing three times 
by repeated centrifugation (400 g for 10 min) and resuspension, 
the cells were finally resuspended in MEM containing 1% gelatin 
(MEM/gelatin) at a density of 107 cells/ml. 
Measurement of  Protein and Lipids.  Protein concentrations were 
measured using a BCA assay  kit (Pierce Chemical Co., Rockford, 
IL). Cholesterol and phospholipid concentrations were measured 
using enzymatic kits (Wako Chemicals  USA, Richmond, VA). The 
phospholipid assay quantifies the choline-containing glycosphin- 
golipids, including sphingomyelin, but not glycosphingolipids. 
SDS-PAGE and Western  Blotting.  Electrophoresis  was performed 
on 15% gels under reducing or nonreducing conditions according 
to the method of Laemmli (13). Nitrocellulose membrane (Bio- 
Pad Laboratories) was used for Western blotting. Unbound pro- 
tein sites were blocked  by incubation with PBS containing 2% BSA 
(PBS/BSA). Thereafter, anti-CD59-reactive bands were detected 
by sequential incubations with mAb anti-CD59 (BRIC  229; 1 
#g/ml in PBS) and GAM-AP (diluted according to the manufac- 
turer's instructions). Blots were developed using a chromogenic 
alkaline phosphatase substrate (Bio-Rad Laboratories). 
Dot Blotting.  Dot blotting was used for rapid detection of  CD59 
in fractions eluted from columns and for semiquantitative  measure- 
ments. Aliquots (2/~1) of  each fraction were spotted onto nitrocel- 
lulose membrane. After drying the membrane was blocked and 
stained as described above for Western blots. 
ELISA for CD59.  Microtiter plates were coated with mAb 
MEM 43.5 (anti-CD59; 1/~g/ml) overnight at 4~  and unbound 
protein  sites were blocked by incubation with PBS/BSA/0.1% 
Tween 20 for I h at 37~  After washing twice in PBS/0.1% Tween 
20, standards and samples (diluted in PBS/0.1% NP-40) were ap- 
plied in triplicate and incubated for I h at 37~  Wells  were washed 
twice, incubated with biotin-labeled mAb YTH 53.1 (anti-CD59; 
1/~g/ml) overnight  at 4~  washed  twice, and incubated  with Strep- 
tavidin peroxidase  (Amersham,  Cardiff',  UK; diluted 1:1,000 in PBS) 
for I h at 37~  and washed two more times before development 
using a chromogenic  horseradish  peroxidase  (HRP) substrate (Sigma 
Chemical Co.). 
PIPLC  Treatment.  To cleave the GPI  anchor of SP  CD59, 
purified protein (50/zg/ml in PBS/0.2% NP-P40) or fresh, unfrac- 
tionated, undiluted SP was incubated with PlPLC (0.1 U/m1) for 
2 h at 37~ 
Removal of GPI-anchored proteins from washed spermatozoa 
was achieved by incubating the cells (107/ml in MEM/gelatin) 
with PIPLC (0.1 U/ml) for 1 h at 37~  The cells  were then washed 
by centrifugation at 400 g for 10 min and used immediately. 
Phase Separation of SP and CD59 in Solution of Triton X-114.  To 
determine whether SP CD59 was amphiphilic or hydrophilic, ex- 
periments were conducted according to the method of  Bordier (14) 
with minor modifications.  Briefly,  SP (100/~1) or purified  SP CD59 
(10/~g in 100 #1 PBS) was diluted in 100/~1 of Tris/NaCl (10 mM 
Tris-HC1, 150 mM NaCI, pH 7.4) containing 0.5% Triton X-114 
at 0~  The solution was incubated at 30~  for 3 min after which 
condensation of the detergent occurred (as evidenced  by clouding). 
The detergent and aqueous phases were separated by centrifuga- 
tion at 2,500g for 3 min at room temperature; the detergent phase 
formed an oily droplet at the bottom of the tube. The aqueous 
phase was collected and extracted twice more with 0.5% Triton 
X-114. Finally, the three detergent phases were pooled and the 
aqueous phase was rinsed with 2% Triton X-114 (the detergent 
phase from this rinse was discarded). Aqueous  and detergent phases 
were dialyzed separately  against PBS and aliquots (20 #1) of these 
and of the input sample were analyzed  by SDS-PAGE and Western 
blotting. SP and CD59 treated with PIPLC were subjected to the 
same analysis. 
Purification of CD59 from SP.  Samples of frozen, cell-free SP 
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(1 raM), EDTA (5 mM), and PMSF (2 raM) were added and the 
pool was centrifuged at 10,000 g for 30 rain to remove any residual 
debris. NP-40 was added to a final concentration of 2%. The pool 
was agitated at 4~  for 1 h, diluted 10x  in PBS containing the 
protease inhibitors listed above, and filtered  through a glass sin- 
tered funnel. The diluted, filtered plasma was applied to a column 
of mAb anti-CD59 (BRIC 229) coupled to Sepharose 4B, which 
had been equilibrated in PBS/0.2% NP-40 containing the addi- 
tives listed above. After washing the column with five column 
volumes of the same buffer, bound protein was eluted with 50 mM 
diethylamine/0.2% NP-40 (pH 11.0). pH was normalized by col- 
lection of fractions into 1 M Tris/HCl (pH 7.4) containing 0.2% 
NP-40. CD59-containing fractions were identified by dot blotting, 
pooled, dialyzed against  PBS/0.2% NP-40, and concentrated to 
500 I~g/ml in an ultracentrifugation cell using a PM10 membrane 
(Amicon Corp., Beverly, MA). SP CD59 was further purified from 
this preparation by a second chromatography with the same column. 
The final sample  was concentrated to 200/~g/ml. 
Radiolabeling of  SP CD59 and Incorporation into GPE.  SP CD59 
(50/~g in 0.4 ml PBS/NP-40) was labeled with 12sI using deriva- 
tized chloramine T (Iodobeads; Pierce and Warriner, Chester, UK) 
according to the manufacturer's instructions. Free iodine was re- 
moved by extensive dialysis. The specific activity of the labded pro- 
tein was 0.5-1 gCi/gg.  The radiolabeled  protein was incubated 
at various  concentrations with GPE (5  x  106/ml,  200 #1 total 
volume) for 15 rain at 37~  The cells were washed three times 
in cold veronal-buffered saline containing 1% gelatin (GVB) to re- 
move unbound protein, and bound radioactivity was  then mea- 
sured in a gamma counter. 
Pro~'n Sequence Analysis of  SP CD59.  Amino-terminal sequence 
analysis using 24-nmol samples of reduced and alkylated protein 
was performed by D. McCourt (Howard Hughes Medical  Insti- 
tute's Protein Chemistry Facility, Washington University School 
of Medicine, St. Louis, MO), using a gas phase sequencer (470A; 
Applied Biosystems,  Inc., Foster City, CA). 
High-S~edCemrifugationofSP.  Aliquots (500/~1) of fresh, cell- 
free SP were centrifuged at 200,000 g for I h at 4~  in a benchtop 
centrifuge (T100;  Beckman Instruments,  Inc.,  Fullerton,  CA). 
Supernatant  was  decanted  into  a  separate  tube  and  the  pellet 
resuspended in a volume of PBS equal to the original volume of  SP. 
~t v~fo,~nce L~qu~ Chro,nat,'e,~t'~  (FV~) Anatm of  sR  sp 
was fxactionated using an FPLC system consisting ofa P-500 pump 
and an LCC-500 liquid chromatography controller froth from Phar- 
macia Fine Chemicals,  Piscataway, NJ) by the following technique. 
Two Superose 6 HR 10/30 columns (Pharmacia Fine Chemicals), 
each with a bed volume of 25 ml, were connected in series. SP 
(1.5 ml) was diluted 1:1 with column eluant (saline/1 mM EDTA/ 
0.02% NAN,) and applied to the columns. Fractions were duted 
at 0.35 ml/min and 90 ￿  0.5-ml fractions were collected. The con- 
centrations of protein, phospholipid, and cholesterol in each frac- 
tion were measured and CD59-containing fractions were identified 
by dot blotting (2/A) and Western blotting (15/~1) of each fraction. 
Cell Bindin$ Assay.  This assay was used to determine whether 
proteins present in SP or in purified or partially purified prepara- 
tions had the ability to bind to cell membranes. 3T3 or 3T3-MCP 
cells were suspended in PBS/2% BSA at a density of 107/ml. Ali- 
quots (100 #1 =  106 cells) were incubated with the samples to be 
assayed (100/zl) for 30 min at 37~  (unless otherwise stated). Cells 
were then washed three times with I ml cold PBS/BSA to remove 
unbound protein, incubated with first antibody (1/zg/ml of mAb 
BRIC 229 anti-CD59, 2/zg/ml ofmAb anti-DAF IA6, or 2/zg/ml 
ofmAb anti-MCP GB24) for 30 min at 4~  washed three times, 
and incubated with second antibody (GAM-FITC, diluted according 
to instructions) for 30 min at 4~  before final washing and anal- 
ysis by flow cytometry on a FACS 440  |  (Becton Dickinson & Co., 
Mountain View, CA). Cells incubated with assay sample and then 
with NIMIg instead of first Ab and cells incubated with PBS in- 
stead  of assay sample  served as controls. 
MAC Inhibition Assay.  The following assay was used to mea- 
sure the MAC inhibitory activity of CD59 present in SP or in 
purified or partially purified preparations. GPE (5% suspension in 
GVB) were incubated with NHS-C9D (final dilution,  1:10) and 
CVF (1/zg/ml) for 30 min at 37~  to form C5b-8 sites on the 
cells (ECSb-8).  ECSb-8 were washed three times and resuspended 
in GVB at a density of 5% before use. Aliquots (100/zl) of the 
cells were incubated with 100 #1 of the sample  to be tested (or 
100 gl GVB for control cells) for 30 min at 37~  unless otherwise 
stated.  After washing three times with 1 ml of cold GVB to re- 
move unbound protein, cells were incubated with purified C9 (2 
/~g/ml in 200/zl GVB) for a further 30 rain. After centrifugation, 
percent hemolysis was estimated by measuring the OD of the su- 
pernatant at 412 nm in a plate reader (MR700; Dynatech Labora- 
tories Inc., Chantilly, VA). In some experiments, ECSb-7, rather 
than ECSb-8, were generated by incubation of GPE with NHS- 
C8D (final concentration, 1:20) and with CVF (1/zg/ml). After 
incubation with samples to be tested and washing to remove un- 
bound protein, MACs were completed on the cells by addition of 
C8 and C9 (each 5 #g/ml). 
The effect of depletion of CD59 from SP on this fluid's MAC 
inhibitory activity was investigated. SP (100 gl) was incubated with 
mAb anti-CD59 (BRIC 229) coupled to Sepharose 413 (solid phase 
anti-CD59;  100/zl) for 1 h at 4~  Solid phase anti-CD59 was 
removed by centrifugation and depletion of CD59 from the SP was 
confirmed by dot blotting. SP incubated with Sepharose 4B cou- 
pled to NIMIg (solid phase  NIMIg) served as a control. 
The extent to which CD59 that was bound to ECSb-7 or ECSb-8 
could be blocked by anti-CD59 Ab was determined. To do this, 
the cells were fast incubated with CD59-containing material (pure 
CD59, SP, or fractions of SP), then washed and incubated with 
either F(ab)2 mAb anti-CD59  (YTH 53.1;  50/zg/ml)  or with 
polyclonal anti-CD59 (Rb476; 100/zg/ml) for 15 rain. Cells were 
then washed and C8 and C9 were added before analysis as described 
above. 
Electron Mi~roscotT.  Pellets produced by high-speed centrifuga- 
tion, either of unfractionated SP or of pooled CD59-containing 
fractions from FPLC of  SP, were fixed in modified Karnovsky's fixa- 
tive (2% glutaraldehyde,  1% paraformaldehyde,  2 mM CaCI2 in 
0.08 M  sodium cacodylate buffer) for 2 h, postfixed in osmium 
tetroxide (1%), dehydrated in graded ethanols, and embedded in 
Spurr's embedding resin. Sections were mounted on 200-mesh nickel 
grids, counterstained with uranyl acetate and lead citrate, and viewed 
on a transmission electron microscope (TEM). 
ImmunoelectronMicroscotTofVesides.  Immunoelectron mieros- 
copy of vesicles present in the CD59-containing fractions from FPI.C 
of SP was conducted by a modification of the method of Watts 
et al. (15). Briefly, droplets (10 gl) of pooled, vesicle-containing 
fractions were placed on formvar-coated nickel grids and left un- 
disturbed at room temperature for I rain. Excess liquid was blotted 
off  with filter paper. The grids were then incubated with 50% rabbit 
serum in PBS (50/zl) for 30 min and washed by sequential incuba- 
tion in 3  x  50-/zl aliquots of PBS for 1 min each. Excess liquid 
was again blotted off and the grids were incubated either with first 
Ab (BRIC 229; 20/zg/ml in PBS), with NIMIg (20/~g/ml), or 
with irrelevant primary antibody (UPC-10, 20/~g/mi; Sigma Chem- 
ical Co.) for 30 min at room temperature.  After washing three times 
1411  Rooney et al. in PBS the grids were incubated with GAM-gold (diluted according 
to manufacturer's  instructions)  for I h at room temperature,  washed 
a further three times, and then fixed  and counterstained  by incuba- 
tion with uranyl  acetate  in 50% ethanol for I min before  viewing 
in the microscope.  In some experiments,  vesicles  were  fixrxt  with 
2% paraformaldehyde  or permeabilized  with 30% methanol be- 
fore the blocking step. 
Table  1.  Binding of Purified Proteins and SP Proteins to 
Murine Fibroblasts 
Mean fluorescence 
Test sample  First Ab  3T3  3T3-MCP 
PBS 
Results  PBS 
Identification  of  CD59 in Samples of  SP.  Samples  of SP, sub-  PBS 
jected to SDS-PAGE under nonreducing conditions followed  PBS 
by Western blotting, contained an anti-CD59-reactive band  PBS 
of 20 kD that comigrated with E CD59 (Fig. 1). This band  mCD59 
was detected in all SP samples tested, including 15 samples  mCD59 
from men who were presumed fertile and four samples from  mDAF 
vasectomized  men whose semen was azoospermic  (not shown). 
The concentration of CD59 in samples of SP from four fer-  mDAF 
tile donors was found by ELISA to be 19.7, 24.5, 17.6, and  sDAF 
15.9 /~g/ml (mean,  19.4/~g/ml; SD, 3.7).  sDAF 
Ability of CD59 in SP to Bind Cell Membranes.  The up-  SP 
take of SP CD59 by heterologous, CD59-negative cells was  SP 
demonstrated using two routine fibroblast cell lines (Table  SP 
1). The first was the 3T3 line, cells of which are negative  SP 
for the human GPI-linked proteins CD59 and DAF, and for 
the human transmembrane protein MCP (CD46). The second 
was the 3T3-MCP line, cells of  which are negative for CD59 
and DAF but express high levels of MCP. After incubation 
with purified CD59 (GPI anchor positive), washing and anal- 
),sis by immunofluorescent staining, and flow cytometry, cells 
of  both lines were CD59 positive. Cells incubated with mDAF 
(anchor positive) were rendered DAF positive whereas those 
incubated with sDAF (anchor negative) remained DAF nega- 
tive. These data established that binding of these proteins 
to cells requires a GPI anchor. 
SP retained CD59 with the ability to bind to cells even 
after storage at 4~  for 1 wk. Although we detected DAF 
in SP by Western blotting (not shown), cells incubated with 
Figure  1.  Detection of  CD59 
in SP. Shown is a Western blot of 
a 15% SDS-PAGE  gel, stained for 
CD59.  Lane I, molecular  mass 
markers; lane 2, purified E CD59 
(1 /~g); lane 3,  unprocessed SP 
(1o  ~,l). 
-  5  4 
NIMIg  5  4 
Anti-CD59  5  4 
Anti-DAF  6  5 
Anti-MCP  7  250 
NIMIg  6  5 
Anti-CD59  42  44 
NIMIg  4  4 
Anti-DAF  29  34 
NIMIg  4  3 
Anti-DAF  7  6 
NIMIg  6  5 
Anti-CD59  40  70 
Anti-DAF  7  10 
Anti-MCP  8  280 
3T3 or 3T3-MCP cells (106 cells in 200 ~1) were incubated with PBS, 
mCD59 (6/zg/ml in PBS), mDAF (10/xg/ml in PBS), sDAF (10 ~tg/ml 
in PBS), or SP (50%  in PBS) for 30 min at 37~  washed,  incubated 
with primary Ab or with NIMIg as stated, washed, and incubated with 
FITC-labeled second Ab before analysis by flow cytometry. Unstained 
cells were used to set the gate. 10,000 events were counted in each case. 
Mean fl, mean fluorescence. 
SP remained DAF negative. The characterization of DAF in 
SP is under further investigation. 
MAC Inhibitory Activity of CD59 in SP.  Incubation of 
EC5b-8 with SP inhibited lysis of these cells on subsequent 
addition of C9 (Fig. 2 A). Cells were washed before exposure 
to C9, indicating that the effect depended on binding of  pro- 
tein to the cell membrane. Percent inhibition of  lysis increased 
with the concentration of SP. Maximal inhibition (>90%) 
was observed when 2.5% SP was used but significant inhibi- 
tion occurred at much lower doses. Preincubation of SP with 
solid phase anti-CD59 reduced the MAC inhibitory activity 
of this fluid by >50%.  Incubation of SP with solid phase 
NIMIg had no effect  on MAC inhibitory activity (not shown). 
Immunofluorescent staining  showed  that  3T3  cells in- 
cubated with SP acquired bound CD59 molecules. The quan- 
tity bound increased with the dose of SP up to 50% (Fig. 
2 B). Binding of CD59 to 3T3 cells incubated with SP oc- 
curred in a time-dependent manner during the first 30 min 
of incubation.  Thereafter, only a small additional increase in 
binding was observed (Fig. 2 C). Pretreatment of SP with 
PlPLC prevented binding of CD59 to 3T3 cells (Fig. 2 D), 
indicating that binding depended on a GPI anchor. No de- 
crease was observed in the amount of SP CD59 that bound 
to 3T3 cells when 10 mM EDTA was added to SP (Fig. 2 E). 
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Figure 2.  Ability  of  CD59 in SP to bind cells. Each 
pand is representative of at least three experiments. 
(A) Inhibitory  effect of  SP on Cg-mediated hemolysis 
of ECSb-8: dose dependence and effect of immuno- 
affinity depletion Of  CD59 from SP. EC5b-8 (5% sus- 
pension in GVB) were incubated with SP at the stated 
doses  for  30  rain at  37~  washed,  and exposed 
to C9 (2/zg/ml) for 30 min at 37~  for 50 rain before 
centrifngation and estimation of percent hemolysis  by 
measurement of the OD of the supernatant at 414 nm. 
(O) SP preincubated with solid-phase  NIMIg, and (0) 
SP incubated with solid-phase anti-CD59. Points are 
the means of triplicates and error bars represent SD 
of the triplicates. (B-E) Binding of CD59 in SP to 
3T3 cells. Aliquots of 3T3 cells (106 cells in 100/zl 
PBS/BSA) were incubated  with dilutions of SP in 
PBS/BSA or with PBS/BSA alone (100/zl) under the 
conditions described  below, washed, stained for CD59, 
and analyzed by flow cytometry. Unstained  cells were 
used to set the gate and 10,000 events were counted 
in each case. (B) Effect of  varying  doses Of  SP on mean 
fluorescence  of  3T3 calls stained for CD59. Cells were 
incubated  with SP at the concentrations stated for 30 
rain at 37~  before washing and staining. (C) Time 
course of binding of CD59 in SP to 3T3 cells. Cells were incubated with 50% SP at 37~  for the times stated before washing and staining.  (D) 
Effect of pretreatment  of SP with PIPLC on binding  of SP CD59 to 3T3 cells. 50% SP (in PBS/BSA) was incubated with or without PlPLC (1 U/m1 
at 37~  for 30 rain). Cells were then incubated with the PlPI,  C-treated  or untreated SP for 30 min at 37~  before washing and staining. (E) Effect 
of inclusion of 10 mM EDTA on the ability of SP CD59 to bind 3T3 cells. Cells were incubated with 100% SP with or without 10 mM EDTA 
or with PBS/BSA alone for 30 min at 37~  before washing and staining. Values  are the means of triplicates and error bars represent SD of the triplicates. 
(F) Binding of CD59 in SP to spermatozoa. Washed spermatozoa and washed, PlPLC-pretreated spermatozoa (both suspended at a density of 107/ml) 
were incubated with SP (50%  in MEM/gelatin) or with MEM/gelatin alone for 4 h at 37~  before washing and staining for CD59 as described 
for the 3T3 cells. NIMIg control represents cells incubated with NIMIg in place of first fib during the immunofluorescent staining procedure. Values 
are the means of triplicates and error bars represent SD of the triplicates. 
CD59 present in SP was also able to bind washed human 
spermatozoa  (Fig. 2 F).  Mean fluorescence of spermatozoa 
incubated with MEM/gelatin in the absence of SP for 4 h 
and then stained for CD59 was 165  _+  4  U, whereas cells 
incubated with SP for the same period had mean fluorescence 
193  _  1 U. PlPLC treatment reduced mean fluorescence of 
spermatozoa stained for CD59 by >50%. P/PLC-treated cells 
incubated with MEM/gelatin and stained for CD59 had mean 
fluorescence 70 _  4 U, whereas those incubated with SP had 
mean fluorescence  87 _+ 2 U. Spermatozoa were at least 95% 
motile at the end of these experiments. 
Purification and  Characterization of  CD59 from Pooled 
SP.  CD59 was purified from pooled SP by affinity chroma- 
tography.  After one filtration  through the immunoaffinity 
column the preparation  contained  a major protein band of 
20 kD plus contaminating low molecular mass material. After 
a second pass over the same column the preparation contained 
a single 20-kD band (Fig. 3 A). This 20-kD band reacted 
strongly with mAb anti-CD59 in the region of 17-25 kD 
(Fig. 3 B) on Western blotting. Final yield of SP CD59 was 
17 lzg/ml SP, consistent with the results obtained by ELISA 
of whole SP. Edman degradation of this protein revealed an 
amino-terminal sequence from residues 1 to 38 that was iden- 
tical  to  that  reported by Davies  et  al.  (8)  for E  CD59. 
No residue could be identified at position  18,  suggesting 
that, as for the E protein, this position  is occupied by an 
N-glycosylated Ash residue. 
Radiolabeled SP CD59 incorporated  into GPE in a dose- 
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Figure 3.  Purification  of SP  CD59.  (A) 
15% SDS-PAGE gel (silver stained). Lane 1, 
molecular  mass markers;  lanes 2  and 3,  SP 
CD59 after the second and first immunoaffinity 
chromatographies,  respectively (3/zg protein 
was loaded in each case); lane 4, unfractionated 
SP (10/zl).  Arrowheads  mark SP CD59. (B) 
Western blot of a 15% gel stained for CD59. 
Lanes I and 2, two samples Of  SP (10 #1 each); 
lanes  3 and 4, SP CD59 after one and two passes 
over the column (1/~g of  protein in each case); 
lane 5, molecular mass markers. Arrowheads 
mark SP CD59. Table  2.  Incorporation of Radiolabeled  8P CD59  into GPE  A 
100 
Molecules  .m 
Input of SP CD59  Counts bound  bound  ~, 
5o  cpra  x  10  J  p.g  cpm  x  103  %  x  103  = 
50  0.25  4.6  9.2  6.9  (1.5) 
20  0.1  3.1  15.5  4.7  (0.9)  g~ 
5  0.025  1.9  37.2  2.8  (1.4)  (~ 
2  0.01  1.0  49.0  1.5  (0.9)  B 
loo 
GPE (107 cells in 0.2 ml GVB) were incubated with varying doses of  ~, 
12Sl-labeled SP  CD59,  washed,  and the cell-bound radioactivity  was 
measured. Molecules bound per cell were calculated from the known spe-  "~ 
cific activity of the labeled protein. Radiolabeled BSA was used as a con-  ~  50 
trol for nonspecific binding of iodinated protein, and the values observed  "~ 
for control cells were  substracted from  the values documented in this  "~ 
table. Results are the means of data obtained in three experiments and 
the numbers in parentheses are the SD of the values from the three ex- 
periments.  C  O" 
100 
dependent manner (Table 2). Aithough the amount of pro- 
tein incorporated increased with the dose of SP CD59, in- 
corporation was more efficient at lower doses. At the lowest 
dose of SP CD59 used (0.01/zg/ml),  49% of the radiola- 
beled  protein bound to the cells. 
SP CD59 inhibited MAC-mediated lysis of EC5b-7 in a 
dose-dependent  manner (Fig. 4 A). When SP, E, and urine 
CD59 were directly compared, the MAC inhibitory activity 
of SP CD59 was between 59 and 75% of E CD59 activity. 
In contrast, urine CD59 (which lacks a GPI anchor) produced 
slight inhibition only at  the highest concentrations  used. 
PIPLC pretreatment  reduced the ability of SP CD59 to in- 
hibit MAC-mediated lysis  of ECSb-8 cells by >70%  (Fig. 
4 B).  Consistent with its known resistance to cleavage by 
PIPLC (16), treatment of E CD59 with PIPLC caused only 
a modest (20-30%) decrease in MAC inhibitory activity (data 
not included). Incubation of EC5b-7 with F(ab)z fragment 
of mAb anti-CD59 (YTH  53.1)  after incorporation of SP 
CD59  and before  addition  of C9  markedly  reduced  the 
inhibition of MAC-mediated lysis attributable to SP CD59 
(Fig.  4 C). 
CD59 Is Present in SP as a GPI-anchored, High Molecular 
Mass Species.  When SP and purified SP CD59 were sub- 
jected to partitioning in solution of Triton X-114, anti-CD59- 
reactive material was detected  only in the detergent  phase. 
In both cases, PIPLC pretreatment of the input sample greatly 
reduced the amount of CD59 partitioning into the deter- 
gent phase (Fig.  5 A). 
10  samples  of fresh,  cell-free  SP  were  fractionated  by 
ultracentrifugation. The precipitated pellets consistently con- 
tained •  10% of the SP protein but >90% of the CD59 (Fig. 
5 B). In other experiments,  silver-stained gels of SP, superna- 
tant,  and  pellet  revealed multiple  protein  bands  in each. 
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Figure 4.  Functional activity of purified SP CD59. (A) Comparison 
of the inhibitory effect of purified CD59 from various sources on C8  + 
C9-mediated hemolysis  of EC5b-7. ECSb-7 (5% suspension in GVB) were 
incubated with purified SP CD59, E CD59, or urine CD59 at the concen- 
trations stated (in GVB) for 30 rain at 37~  After washing the cells were 
incubated with C8 and C9 (each 5/zg/ml in GVB) for 30 min at 37~ 
before centrifugation and estimation of percent hemolysis by measurement 
of the OD of the supernatant at 412 nm. (0) SP CD59; (O) E CD59; 
(I~) urine CD59. (B) Effect of PIPLC treatment on the MAC inhibitory 
activity of purified SP CD59. EC5b-7 were incubated with PlPLC-treated 
or untreated SP CD59 at the concentrations stated (in GVB) for 30 min 
at 37~  before washing, exposure to C8 and C9, and estimation of per- 
cent hemolysis as described in Fig. 3 A. (O) Untreated SP CD59; (@) 
PlPLC-pretreated SP CD59. (C) Effect of F(ab)2 fragment of mAb anti- 
CD59 YTH 53.1 on the MAC inhibitory activity of SP CD59. ECSb-7 
were incubated with purified SP CD59 at the concentrations  stated for 
30 rain at 37~  washed, and incubated with F(ab)2 fragment  of mAb 
anti-CD59 (YTH 53.1; 50/zg/ml in GVB) or with GVB alone for  15 
min at 37~  before washing, exposure to C8 and C9, and estimation of 
percent hemolysis as described in Fig. 3 A. (@) SP CD59-treated ECSb-7 
cells that were incubated with F(ab)2 anti-CD59; (O) those that were in- 
cubated with GVB alone. In each case, points are the means of triplicates, 
error bars represent SD of the triplicates, and data are representative of 
at least three experiments. 
the CD59.  Purified preparations of E CD59 and SP CD59 
were not precipitated by ultracentrifugation. 
SP and the high-speed pellet  and supernatant were com- 
pared with respect to their content of functionally active CD59 
1414  CD59 in Seminal Plasma Figure 5.  Further characterization of CD59 
in SP: detergent phase partitioning  and p~pi- 
ration by ultracentrifugation  of SP. (A) Parti- 
tioning of SP CD59 in solution of Triton X-114. 
Unprocessed SP and purified SP CD59 were 
incubated with or without PIPLC (0.1 U/ml) 
for 2 h at 37~  and then subjected to analysis 
by phase separation in solution of Triton X-114 
as described in Materials and Methods. Shown 
is a Western blot of a 15%  SDS-PAGE gel, 
stained  for  CD59,  on which the  detergent 
phases collected from the Triton X-114  experi- 
ment were  loaded.  Lane 1,  molecular  mass 
markers; lane 2, untreated SP (detergent phase); 
lane 3;  PIPI.C-treated  SP (detergent  phase), 
anti-CD59-reactive  material was much reduced; 
lane 4, purified SP CD59 (detergent  phase); 
lane  5,  PlPLC-treated  SP  CD59  (detergent 
phase),  anti-CD59-reactive  material  was  no 
longer detected. (8) Ultracentrifugation  of SP. 
SP (1 ml) was subjected to ultracentrifugation 
at 200,000 g for 1 h. Shown is a Western blot 
of a 15% SDS-PAGE gel, stained for CD59. 
Lane I, molecular mass markers; lane 2, purified 
SP CD59 (3/~g); lane 3, unfractionated SP (15 
/~1); lane 4, ultracentrifugation  pellet (15/~1 of 
a pellet resuspended in a volume of PBS equal 
to  the  original volume  of SP), anti-CD59- 
reactive material was present; lane 5, ultracen- 
trifugation supernatant (15/~1), only  very slight 
anti-CD59 reactivity  was detected. (C) Binding 
of SP CD59 to 3T3 cells incubated with SP 
and the ultracentrifugation pellet and super- 
natant. 3T3 cells were incubated with SP or with the ultracentrifugation  pellet or with the supernatant for 30 min at 37~  washed, stained for CD59, 
and analyzed by flow cytometry. 10,000 events were counted in each case. The figure is representative of three experiments. (D) MAC inhibitory  activity 
of SP and the ultracentrifugation  pellet and supernatant. ECSb-8 were incubated with samples to be tested (100/~g/ml of protein) or with GVB (control 
cells) for 30 min at 37~  washed,  and incubated with polyclonal anti-CD59 IgG (100/xg/ml) or NIRIg (100/~g/ml) for 15 min at 37~  before 
exposure to C9 and estimation of percent hemolysis as described in Fig. 1 A. Values are the means of triplicates and error bars represent SD of the 
triplicates. The data  are representative of three experiments. 
by cell binding and MAC inhibition assays. 3T3 cells  incubated 
with the resuspended pellet before staining with anti-CD59 
and FITC-labeled second Ab had a mean fluorescence greater 
than fourfold that of cells incubated with unfractionated SP; 
the increased ability of CD59 present in the resnspended pellet 
to bind cells may be due to the absence of inhibition by lipo- 
proteins present in SP (see  Discussion). In contrast, the fluores- 
cence of cells incubated with supernatant  was only slightly 
increased relative to control cells (Fig. 5 C). 
Lysis of ECSb-8 cells on exposure to C9 was inhibited by 
56  _+  5% when the cells were incubated with SP. Incuba- 
tion of the cells with anti-CD59 after incubation with SP 
and before exposure to C9 abrogated this inhibitory activity 
by ;>50%. The resuspended pellet gave a degree of inhibi- 
tion comparable to that achieved with SP (51 +  1%), which 
was also abrogated by >50% when anti-CD59 was included 
in the system. In contrast, incubation of  EC5b-8 with super- 
natant inhibited their subsequent lysis by 26  _+ 8%, and this 
inhibitory activity was not significantly reduced by inclusion 
of anti-CD59 in the assay (Fig.  5 D). 
The above data indicate that SP CD59 possesses a GPI an- 
chor and is present  in SP in a high molecular mass form. 
FPLC Fractionation of  SP.  Samples  of  SP from four donors 
were analyzed by FPLC on Superose 6.  Protein,  phospho- 
lipid, and cholesterol content of fractions from a representa- 
tive experiment are shown in Fig. 6. Protein duted in two 
bands:  an early, minor band present in the void volume of 
the column (fractions 4-14) and a later, broad band containing 
the bulk of the protein (fractions 20-85).  Phospholipid  also 
eluted in two bands: an early, minor band that coeluted with 
the early protein band, while the bulk of the phospholipid 
was detected in a later band (fractions 50-80).  Cholesterol 
coeluted with the early protein and phospholipid bands and 
was not detected in later fractions. Anti-CD59-reactive  ma- 
terial of 20 kD (detected by Western blot) was present  in 
fractions of the early protein-, phospholipid-, and cholesterol- 
containing band, and was not detected in later fractions. 
CD59-containing fractions were pooled. Total protein con- 
tent of the pool was 1.1  _+  0.1 mg (mean of four experi- 
ments). Cholesterol was measured in three experiments; values 
were 0.8, 0.83, and 0.73/~g cholesterol/mg protein.  Phos- 
pholipid was measured in two experiments. Phospholipid/cho- 
lesterol ratios  (/~g//~g) were 1:1.5 and 1:1.4. 
Comparable  data were obtained  when pools  of CD59- 
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Figure 6.  FPLC fractionation of 
SE (.4) Results of biochemical anal- 
ysis of fractions (94  x  0.5 ml) from 
FPLC analysis of SP (1.5 ml) on Su- 
perose  6.  (O)  Cholesterol;  (e) 
phospholipid; (11) protein. (B) Bio- 
chemical analysis of fractions  1-30 
from FPLC analysis of SR Note that 
in  this  case  the  scale for  protein 
and lipid is in/~g/ml. Symbols are 
as in A. 
containing fractions from three donors were analyzed by SDS- 
PAGE and Western blotting. Unfractionated SP contained 
multiple protein bands.  Pooled CD59-containing fractions 
also displayed multiple bands, although fewer bands than were 
present in SP. These included a major band that comigrated 
with SP CD59 (Fig. 7 A) and reacted with anti-CD59 (Fig. 
7 B). Densitometry of the silver-stained gels indicated that 
the 20-kD band comprised 13.2, 12.0, and 16.8% of the total 
protein in the respective pools. The mean CD59 content of 
pooled vesicles from three separate preparations was 12.6% 
of total protein (129/~g/mg of total protein; SD, 29). These 
data were in agreement with those obtained by both semi- 
quantitative dot blotting and Western blotting. 
CD59 activity in the pools was investigated by MAC in- 
hibition assay. Incubation of EC5b-8 cells with the pooled 
material at a protein concentration of 100 #g/ml inhibited 
their lysis on subsequent exposure to C9 by 47  _+  4%. 
7?ansrnission Electron Microscopy.  On examination by TEM, 
the pellet obtained by ultracentrifugation of SP was found 
to consist of a dense population ofbilamdlar vesicles (10-200 
nm in diameter), together with an amorphous substance that 
we have not identified (Fig. 8 a). The ultracentrifugation pellet 
of pooled CD59-containing fractions from FPLC of SP con- 
sisted almost entirely of vesicles without contaminating ma- 
terial  (Fig.  8 b). 
Unfixed vesicles  placed on formvar-coated grids and probed 
with anti-CD59 and gold-labded secondary Ab stained posi- 
tively for CD59 (Fig.  8, c and d). When the vesicles were 
fixed in 2% paraformaldehyde or permeabilized with 50% 
methanol before staining, the number of beads present per 
vesicle was unaffected. Of 100 vesicles selected at random 67 
had gold particles, and the mean number of gold beads per 
vesicle was 1,0. The mean number of gold beads per vesicle 
when only stained vesicles  were counted was 1.5 (range, 1--4). 
No gold beads were present on the matrix between vesicles 
and no gold particles were associated with control vesicles 
incubated with NIMIg or with irrelevant primate antibody 
in place of first antibody. 
Discussion 
We here report the presence in SP of the MAC inhibitory 
protein CD59 at a concentration of at least 20 #g/ml. This 
protein, SP CD59, was apparently identical with E CD59 
in terms of molecular mass, antigenicity,  and amino-terminal 
amino acid sequence. Moreover, it had the capacity to bind 
to the membranes of GPE, murine fibroblasts,  and human 
spermatozoa even when present in unfractionated SP, indi- 
cating that this phenomenon may occur in vivo. Incubation 
of heterologous E with SP rendered the cells more resistant 
to lysis by human MACs. The MAC inhibitory capacity of 
SP could be partly removed by immunoafl~nity depletion of 
CD59 from this fluid and partly abrogated by incubation of 
SP-treated ECSb-8 cells with anti-CD59 Ab before exposure 
Figure  7.  Analysis of vesicles  purified from SP by FPLC 
analysis. (/1) Silver-stained, 15% SDS-PAGE gel. Lane I, 
molecuhr mass markers; lane 2, purified SP CD59 (3 #g); 
lane 3, vesicles purified by FPLC (3 #g): multiple protein 
bands are present, including a 20-kD band; lane 4, un- 
fractionated SP, a greater number of bands are present than 
in lane 3, including a 20-kD band (arrowheads). (B) Shown 
is a Western blot of a 15%  gel stained for CD59.  Lane 
I, molecular mass markers; lane 2, purified SP CD59 (1 
/~g); lane 3, FPLC-purified vesicles (2/~g); lane 4, unfrac- 
tionated SP (20/~g). 
1416  CD59  in Seminal Plasma Figure 8.  Electron  microscopy.  (a) Shown  is TEM of a pellet obtained  by ultracentrifugation  of SP. The pellet was fixed, embedded  in resin, and 
sectioned as described  in Materials  and Methods. Bilamdlar  vesicles are present, together  with an amorphous  material (x19,250). The bar represents 
200 nm. (b) TEM of a pellet obtained  by ultracentrifugation  of FPLC purified  vesicles. The pellet was fixed,  embedded, and sectioned  as described. 
Vesicles are almost free of contaminating  material (x38,500). The bar represents 100 nm. (c) FPLC-purified  vesicles that were stained  unfixed  with 
anti-CD59 and gold-labeled  secondary  antibody  and viewed  without embedding  or sectioning. The field  shows one veside, with two gold particles 
at the periphery. The surrounding  matrix is free of gold particles (x 77,000). The bar represents 50 nm. (d) FPI.C-purified  vesicles stained  as in c after 
fixation  in paraformaldehyde  (2%). The field shows three vesicles, one with three gold particles (I), one with one gold particle (2), and one without 
gold particles (3). The surrounding matrix is free of gold particles (x 77,000). The bar represents 50 nm. 
of the cells to C9, strongly suggesting that SP CD59 was 
at least partly responsible for the MAC inhibition. Binding 
of SP  CD59  to  3T3  cells  occurred in  a  time-  and dose- 
dependent manner. Failure of 100% of the CD59 present in 
SP to bind to cells may be due to the influence of  lipoproteins 
in SP: lipoproteins present in serum are known to inhibit 
binding of purified GPI-linked proteins to cell membranes 
(17,  18). 
Pretreatment of SP or of purified SP CD59 with PIPLC 
markedly reduced the capacity of SP CD59 to bind cells and 
to inhibit their lysis by human MACs, and greatly decreased 
the amount of SP CD59 that partitioned into the detergent 
phase of Triton X-114  (Fig. 4 A). These data provide com- 
pelling evidence that SP CD59 possesses a GPI anchor. The 
mechanism by which the anchor is retained is of interest. 
We present here evidence  that SP CD59  is carried on the 
surface of vesicular organdies and that cells may acquire new 
CD59 molecules as a result of  interaction with these organelles. 
Analysis of fractions by Western blotting and semiquantita- 
tive dot blot indicated that >90% of SP CD59 was precipi- 
tated by ultracentrifugation of SP. These data were supported 
by cell binding and MAC inhibition assays. PIPLC treatment 
of SP prevented precipitation of SP CD59. We conclude that 
CD59 was present in SP in particulate form and that this 
particularity was GPI anchor dependent. The residual MAC 
inhibitory activity in the high-speed supernatant, together 
with the failure of anti-CD59 to abrogate MAC inhibitory 
activity on supernatant-treated cells or to abrogate completely 
the MAC inhibitory activity of unfractionated SP, may imply 
the function of other cell-binding, MAC inhibitory proteins 
in SP. 
On direct examination by TEM the high-speed pellet was 
found to consist of a population ofbilameUar vesicles (10-200 
nm in diameter) and an amorphous substance that we did 
not attempt to identify. Our observations concur with those 
of Ronquist et al. (19), who named the vesicles "prostasomes" 
(20) and proposed that the amorphous material consists of 
protein deriving from the seminal vesicles (21). We further 
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6.  TEM of the pellet generated by ultracentrifugation of 
phospholipid-, protein-, and cholesterol-containing fractions 
that eluted in the void volume of the columns revealed a clean 
population of vesicles with minimal contaminating material. 
Biochemical analysis of the vesicles established that their com- 
position was broadly comparable with that reported for prosta- 
somes (22). We found the cholesterol content of the vesicles 
to range between 0.73 and 0.83 gg/mg protein, while the 
values reported by Arvidson et al. (22) range from 0.46 to 
0.67/~g/mg. 
All detectable  CD59 was found by Western blotting to 
be associated with the vesicles, and this was confirmed by 
immunoelectron  microscopy and MAC inhibition assay. How- 
ever, our ELISA measurements of CD59 concentration in the 
purified vesicles are not compatible with those that we ob- 
tained for unfractionated SP. For example, the measured con- 
centration of CD59 in SP was '~20/~g/ml and, since 1.5 ml 
of SP was applied to the FPLC system, a total of not more 
than 30 gg recovered protein was expected. However, ~100 
gg of CD59 was recovered (all in vesicle-containlng fractions). 
Semiquantitative Western blotting and dot blotting of SP, 
the ultracentrifugation pellet, and the FPLC-purified vesicles, 
together with data from densitometry analysis of the purified 
vesicles, indicate that the concentration of CD59 in SP is 
~100 ~g/ml and that this protein comprises >10% of the 
total protein content of the vesicles. Together, these data sug- 
gest that the direct ELISA measurements of CD59 in un- 
processed SP underestimate the amount of CD59 that is present 
in this fluid. Comparison of data from several different quan- 
titative assays will be required before a more correct estima- 
tion can be made. We therefore state here that the concentra- 
tion of CD59 in human SP is at least 20 #g/ml, with the 
reservation that the true concentration may be greater. 
Prostasomes are extracdiular, vesicular,  bilamdiar organdies, 
of 150-nm average diameter (20). Although these particles 
possess a number of enzymic activities  (21), promote sper- 
matozoal motility (21), and inhibit mitogen-induced  prolifer- 
ation of lymphocytes (23), our data provide the first direct 
evidence of a physiologically important role for a prostasome 
membrane protein. 
Data from EM suggest that prostasomes are present within 
"storage vesicles" in cells of the prostatic acinar epithelium. 
Two mechanisms have been proposed to operate in their re- 
lease: exocytosis and "diacytosis," the latter being a process 
by which intact storage vesicles are expelled from the cell 
(21). Although we found all detectable SP CD59 to be as- 
sociated with membrane vesicles, semiquantitative analysis 
indicated that the concentration of this protein was greater 
in the SP of fertile men than in that of men postvasectomy 
(our unpublished results). SP CD59 may therefore arise from 
sites on both sides of transection of the ductus dderens. Vesicles 
present in the SP of other species originate from epididymis 
and seminal vesicles (24-26), and it is possible that prosta- 
somes derive from more than one organ. We are examining 
their cellular origin and biosynthesis using cells in culture. 
Bilamellar vesicles released by other cell types in vitro are 
enriched in GPI-anchored proteins, relative to the cell plasma 
membrane (27-29). On cell membranes, GPI-anchored pro- 
teins are preferentially expressed in glycosphingolipid-rich do- 
mains (caveolae) (30, 31). Others have speculated that these 
domains are precursors of endocytic vesicles, although vesic- 
ulation of caveolae has not been demonstrated (30, 31). We 
suggest that prostasomes derive from caveolae. This mecha- 
nism, if correct, suggests a biologic advantage for the GPI 
anchor and a role for vesicles in body fluids. 
Compelling evidence indicates that the interaction of prosta- 
somes with spermatozoa involves hydropbobic bond formation 
(32). Our data could be explained by a continuing associa- 
tion of intact prostasomes with cell membranes. Alternatively, 
CD59 and other membrane proteins might be transferred from 
prostasome membranes to the membranes of the interacting 
cell type. Experiments are in progress to duddate this question. 
Inhibition of C  activation on spermatozoa has been the 
focus of much scientific attention in recent years. Another 
C regulatory protein, MCP, has been localized on spermatozoa 
(33, 34). However, this protein is not exposed, and is there- 
fore unlikely to protect spermatozoa, until after the acrosome 
reaction has occurred (,~7 h  after  entry to the female re- 
productive tract).  The relative abundance of the fluid phase 
MAC inhibitor, SP 40,40, in semen has prompted sugges- 
tions that this may be the most important regulator of C 
activation on spermatozoa (35, 36).  However,  the demon- 
stration that neutralization of CD59 on spermatozoa renders 
the cells highly susceptible to MAC-mediated damage (6) im- 
plies an important role for this protein in vivo. Prostasomes 
may represent a pool of CD59 from which protein lost from 
spermatozoa, possibly as a result of normal membrane turn- 
over or of low level C attack, may be replenished,  thus en- 
suring that the cells reach higher levels of the female reproduc- 
tive tract with a full complement of the protein on their 
membranes. 
Binding of SP CD59 to infective organisms may contribute 
to the persistence  of infection within the male and female 
reproductive tracts. We are therefore investigating the capacity 
of this protein to bind to bacterial  cell walls. 
Finally, the findings presented here may facilitate the de- 
velopment of preparations of membrane-bound GPI-linked 
proteins, including CD59, suitable for use in the therapy of 
C-related and other diseases. 
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